We also used MLN4924 to treat patient-derived orthotopically xenografted (PDX) FN-RMS cells, one of which mutated for p53 (B011_YC) and another expressing p53 wild-type (from two different tumor sites: B012_YC and B012_ZC)43. Here, TP53 is linked to neoplasm.